KIM
GMAB icon

Kestra Investment Management’s Genmab GMAB Stock Holding History

Kestra Investment Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-575
Closed -$12K – 1113
2024
Q4 		$12K Buy
+575
New +$12.6K ﹤0.01% 803

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Kestra Investment Management's GMAB Position: Q1 2025 in Review

Kestra Investment Management sold out of Genmab (GMAB) in Q1 2025, closing a stake of 575 shares — an estimated $12K sold.

Kestra Investment Management first reported a position in GMAB in Q4 2024 and held it in 1 quarter. The position peaked at $12K in Q4 2024. 219 funds tracked by Wall St. Rank hold GMAB as of Q1 2025.

  • Kestra Investment Management reported no remaining Genmab position as of Q1 2025 after selling out during the quarter.
  • Kestra Investment Management sold 575 Genmab shares in Q1 2025, an estimated $12K.
  • Kestra Investment Management first reported a position in Genmab in Q4 2024 and held it in 1 quarter.
  • Kestra Investment Management's Genmab position peaked at $12K in Q4 2024.
  • 219 funds tracked by Wall St. Rank held Genmab as of Q1 2025.

Based on Kestra Investment Management's 13F filing for Q1 2025, filed 16 May 2025.